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Abstract
Background: Large-scale gene expression profiling of peripheral blood mononuclear cells from Rheumatoid Arthritis (RA)
patients could provide a molecular description that reflects the contribution of diverse cellular responses associated with
this disease. The aim of our study was to identify peripheral blood gene expression profiles for RA patients, using Illumina
technology, to gain insights into RA molecular mechanisms.
Methodology/Principal Findings: The Illumina Human-6v2 Expression BeadChips were used for a complete genome-wide
transcript profiling of peripheral blood mononuclear cells (PBMCs) from 18 RA patients and 15 controls. Differential analysis
per gene was performed with one-way analysis of variance (ANOVA) and P values were adjusted to control the False
Discovery Rate (FDR,5%). Genes differentially expressed at significant level between patients and controls were analyzed
using Gene Ontology (GO) in the PANTHER database to identify biological processes. A differentially expression of 339
Reference Sequence genes (238 down-regulated and 101 up-regulated) between the two groups was observed. We
identified a remarkably elevated expression of a spectrum of genes involved in Immunity and Defense in PBMCs of RA
patients compared to controls. This result is confirmed by GO analysis, suggesting that these genes could be activated
systemically in RA. No significant down-regulated ontology groups were found. Microarray data were validated by real time
PCR in a set of nine genes showing a high degree of correlation.
Conclusions/Significance: Our study highlighted several new genes that could contribute in the identification of innovative
clinical biomarkers for diagnostic procedures and therapeutic interventions.
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Introduction
Rheumatoid Arthritis (RA) is an autoimmune disease charac-
terized by chronic and persistent joint synovial tissue inflammation
associated with the destruction of affected joints [1]. The
multifactorial nature of the disease provides a high RA
heterogeneity with specific combinations of a genetic background
and environmental factors that influence the susceptibility, severity
and outcome of the disease [2]. The RA heterogeneity is
demonstrated by the presence of distinct autoantibody specificities,
like rheumatoid factor (RF) and anti-cyclic citrullinated peptide
antibodies (ACPA) in the serum [3,4], the differential responsive-
ness to treatment [5,6], and the variability in clinical presentation.
In addition, several gene expression profiling studies of synovial
tissues and peripheral blood mononuclear cells (PBMCs) from RA
patients showed marked variation in gene expression profiles that
allowed to identify distinct molecular disease mechanisms involved
in RA pathology [7,8]. The relative contribution of the different
mechanisms may vary among patients and in different stages of
disease. Thus, the broad goals of expression profiling in RA are to
(i) improve our understanding of the pathogenic mechanisms
underlying RA, (ii) identify new drugs targets, (iii) assess activity of
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therapy, overall disease severity, and organ specific risk and (v)
develop new diagnostic tests [9].
PBMCs gene expression profiling allows both pathogenetic and
pathophysiological processes identification as demonstrated in
several types of diseases: cancer [10], asthma [11], systemic lupus
erythematosus (SLE) [12], cardiovascular diseases [13] and
psychiatric disorders [14]. Pathogenetic processes are primarily
associated with the cause of a disease. Then, microarrays could
lead to the identification of abnormal genes and gene activities that
may not be only limited to PBMCs, but could occur in cells of
pathological tissue as well. In contrast, pathophysiological changes
in lymphocytic gene expression are considered an essentially
normal reaction of the immune system to a pathological stimulus.
Therefore, pathophysiological gene profiles may be shared in a
variety of diseases, whereas pathogenetic gene expression is
expected to be disease specific [15]. The differences in expression
profiles provide opportunities to stratify RA patients based on
molecular criteria that may require different treatment strategies.
Considering several comparative studies, Illumina and other
microrray technologies have similar performances [16–18].
However, these studies showed that each approach was able to
detect specific genes, meaning an increase in knowledge by each
platform. To complete previous studies on RA with other
microarrays [7], we applied Illumina large-scale gene expression
profiling in PBMCs of RA patients to potentially gain insights into
molecular mechanism of this disease. We identified new genes
involved in different functional Immunity and Defense related
mechanisms as pro-inflammation, anti-microbial activity, cellular
stress and immunomodulatory functions in Rheumatoid Arthritis.
Materials and Methods
Study population
The study and all protocols presented here were approved by
the Ethics Committees of Bice ˆtre and Saint Louis Hospitals (Paris,
France) and all study participants provided written informed
consent. All RA patients satisfied the revised criteria of the
American College of Rheumatology [19] according to the
rheumatologist in charge of the patient. A rheumatologist
university fellow reviewed all clinical data. Characteristics of the
18 RA French Caucasian Patients are reported in Table 1.
Among the control group consisted of 15 RA French Caucasian
healthy individuals, 11 were females (mean 6 Standard Deviation
(SD) age at enrolment 56.9 6 6.6). In all comparisons mentioned,
the groups were age and sex-matched.
Isolation of total RNA
Peripheral blood (PB) was drawn in PAXgene RNA isolation
tubes (PreAnalytix) from 18 patients and 15 controls. Total RNA
was isolated from PBMCs using the PAXgene RNA isolation kit
(PreAnalytix). Total RNA yield (ng) was determined spectropho-
tometrically using the NanoDrop ND-1000 (Wilmington). Total
RNA profiles were recorded using a Bioanalyzer 2100 (Agilent).
RNA integrity numbers were determined and the mean value was
8.07+/20.51 SD and a Coefficient of Variation (CV) of 6.4%.
Probe synthesis, hybridization and detection
cRNA was synthesized, amplified and purified using the
Illumina TotalPrep RNA Amplification Kit (Ambion Inc.)
following manufacturer recommendations. Briefly, 200 ng of
RNA was reverse transcribed. After second strand synthesis, the
cDNA was transcribed in vitro and cRNA labelled with biotin-16-
UTP. Labelled probe hybridization to Illumina BeadChips
human-6v2 was carried out using Illumina’s BeadChip 6v2
protocol. These beadchips contain 48,701 unique 50-mer
oligonucleotides in total, with hybridization to each probe assessed
at ,30 different beads on average. 22,403 probes (46%) are
targeted at Reference Sequence (RefSeq) [20] transcripts and the
remaining 26,298 probes (54%) are for other transcripts, generally
less well characterized (including predicted transcripts).
Beadchips were scanned on the Illumina BeadArray 500GX
Reader using Illumina BeadScan image data acquisition software
(version 2.3.0.13). Illumina BeadStudio software (version 1.5.0.34)
was used for preliminary data analysis. To assess quality metrics of
each run, several quality control procedures were implemented.
Total RNA control samples were analyzed with each run. The
Illumina BeadStudio software was used to view control summary
reports, scatter plots of the total RNA control results from different
days and scatter plots of daily run samples. The scatter plots
compared control against control or sample against sample and
calculated a correlation coefficient (Figure 1). Viewing the scatter
plots determined whether controls across different days varied in
quality, indicating a reduction in assay performance, and
highlighted those samples that were of lower quality. The control
summary report is generated by the BeadStudio software, which
evaluates the performance of the built-in controls of the
BeadChips across particular runs. This allows the user to look
for variations in signal intensity, hybridization signal, background
signal and the background to noise ratio for all samples analyzed
in that run. Data are expressed as log2 ratios of fluorescence
intensities of the experimental and the common reference sample.
The Illumina data were then normalized using the ‘normalize
quantiles’ function in the BeadStudio Software.
All microarray data reported in this study is described in
accordance with MIAME guidelines and have been deposited in
the National Center for Biotechnology Information Gene
Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/)
public repository, and they are accessible through GEO accession
(GSE15573).
Real-Time PCR
Total RNA was reverse transcribed using Superscript III and
oligo(dT) primers (Invitrogen) according to the manufacturer’s
instructions. Real-time quantitative PCR was carried out using the
SYBR-green master mix (Applied BioSystems) in an Mx 3005P
thermocycler (Agilent). PCR conditions were 95uC for 10 min,
followed by 40 cycles of 95uC for 15 sec and, 60uC for 1 min. At
Table 1. Clinical and demographic characteristics of the RA
patients.
Clinical features patients RA Patients (n=18)
Mean age (years) 60
Women (%) 72.3
Caucasian (%) 100
RF-positive (%) 88.9
ACPA-positive (%) 90.9 (out of 11 RA patients)
Mean disease duration (years) 8.6
Erosions (%) 63.2
Disease Activity Score 28 (DAS28) mean 5.22
Disease-Modifying Anti-Rheumatic Drugs use (%) 100
Anti-TNF therapy 0
doi:10.1371/journal.pone.0006803.t001
RA Gene Expression Profiling
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performed to confirm the specificity as well as the integrity of the
PCR products by the presence of a single peak. Gene-specific
primers were designed inside or nearby the microarray sequence
targeted, using Primer Express Software (PE Applied Biosystems).
Primers sequences of all genes analyzed are provided in Table S1.
Absence of cross contamination and primer dimer was checked on
genomic DNA and water. From a list of 8 housekeeping genes
(HKG), we chose HMBS and ALDOA, which meet the criteria of
less variation between samples and compatible expression level
with the studied genes. The geometric mean of HKG expression
was used to normalize the expression of genes of interest [21].
Standard curves were generated from assays made with serial
dilutions of reference cDNA to calculate PCR efficiencies
(100%+/215%, with r
2 .=0.997). Ct samples were transformed
into quantity values using the formula (1+Efficiency)
Ct. Only
means of triplicate with a CV of less than 10% were analyzed.
Inter-plate variation was below 8%.
Statistical analysis
Statistical analysis on microarray data was performed using one-
way analysis of variance (ANOVA) per gene where the normalized
signals are explained by the patient status. One contrast was built
to determine an expression difference between controls and RA
patients [22]. Since the number of individuals is large, the residual
variance was used to calculate the statistic test [23]. The raw P
values were adjusted by the Benjamini-Hochberg procedure,
which controls the False Discovery Rate (FDR) [24]. For the
contrast, a gene is considered differentially expressed if the
Benjamini-Hochberg-corrected P value is less than 0.05.
Genes that were expressed at significantly different levels
between patients and controls were analyzed by supervised
hierarchical clustering (uncentered correlation, complete linkage)
[25] to visualize the correlation of co-expressed genes in Treeview
(available at http://rana.lbl.gov/EisenSoftware.htm).
For an interpretation of the biological processes that are
represented by the genes that show a significantly different level of
expression in RA patients compared to the controls, we applied
Gene Ontology analysis in the PANTHER database at http://
www.pantherdb.org (Applied Biosystems) [26]. PANTHER uses
the binomial statistics tool to compare our gene list to a reference
list (NCBI: Homo sapiens genes) determining the statistically
significant over- or under- representation of PANTHER biological
process [27]. After, for each biological process in PANTHER, the
Figure 1. Scatter plots representation of signal intensities. Scatter plot of technical replicates: (A) same reference RNA undergoing two
different hybridization or (B) same reference RNA from two different labeling runs. Typical scatter plots of data obtained from two patients (C) or a
patient and a control (D). Pearson correlation coefficient is indicated in each scatter plot.
doi:10.1371/journal.pone.0006803.g001
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likelihood that their fold changes were drawn randomly from the
overall distribution of fold changes. The Mann-Whitney U Test
(Wilcoxon Rank-Sum Test) is used to determine the P value that,
say, if specific biological process genes have random fold changes
relative to the overall list of values that was input. A significant P
value indicates that the distribution (fold change) for this category
is non-random and different from the overall distribution [28]. In
both statistical tests, processes with a P value ,0.05 were
considered significant after Bonferroni correction which was
applied to adjust for multiple comparisons. Correlations between
two set of data were measured using Pearson coefficient.
Results
Gene expression profiling in PMBCs of RA patients
Genome-wide transcriptional profiles of PBMCs from 18 RA
patients and 15 age and sex-matched controls were measured on
microarrays that contain 48,701 unique 50-mer oligonucleotides
in total, with a mean ,30 hybridizations per sequence. Data were
analyzed using ANOVA. Using this test with a FDR of 5% we
identified 380 transcripts with significant expression. The
proportion of detected transcripts was substantially higher among
RefSeq genes (91%) than non-RefSeq genes (9%), reflecting the
greater degree of knowledge and certainty about the existence of
RefSeq transcripts. Four genes, represented more than once in this
list, were averaged from sequences with the same Unigene
identifier. Significant difference in expression level between the
two groups was observed for 339 RefSeq genes. Among them, 238
were downregulated (Table S2) and 101 were upregulated
(Table S3). The significant gene expression differences between
RA patients and controls were visualized in a cluster diagram
(Figure 2).
Genes upregulated in RA
To categorize the up-regulated 101 genes into functional
biological groups we used the PANTHER database (described in
Methods section). We observed an elevated expression of a
spectrum of genes involved in Immunity and Defense, nucleoside,
nucleotide and nucleic acid metabolism, signal transduction,
protein metabolism and modification, mRNA transcription,
transport and developmental processes in the peripheral blood of
RA patients compared to controls. Compared to a NCBI Homo
sapiens reference list, the differentially up-regulated genes list
revealed three biological processes significantly over represented
(P,0.05) (Figure 3A). Then, the fold change of the genes
associated to each biological process was compared to the overall
distribution of fold changes. Immunity and Defense was the only
significant functional biological process after Bonferroni correction
(P=0.03) (Figure 3B).
This cluster of genes involved in Immunity and Defense process
contains the S100 family proteins S100 calcium-binding protein
A8 (S100A8), S1000A9 and S100A12, the orosomucoid family
proteins ORM1 and ORM2, as well as other inflammatory
mediators like lymphocyte antigen 96 (LY96), cathelicidin
antimicrobial peptide (CAMP), thioredoxin (TXN), allograft
inflammatory factor 1 (AIF1), nuclear factor of activated T-cells
5( NFAT5), F5 (coagulation factor V), SLC11A1 (solute carrier
family 11, member 1) and PGLYRP1 (peptidoglycan recognition
protein 1). These genes are characterized in Table 2.
Genes downregulated in RA
Compared to the same NCBI Homo sapiens reference list, the
mainstream of the genes that showed a lower expression in RA
Figure 2. Cluster diagram of the expression of 339 significantly
expressed genes in 18 RA patients and 15 controls. Genes are
organized by hierarchical clustering based on overall similarity in expression
patterns. Red represents relative expression greater than the median
expression level across all samples, and green represents an expression
level lower than the median. Black indicates intermediate expression.
doi:10.1371/journal.pone.0006803.g002
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nucleoside, nucleotide and nucleic acid metabolism, mRNA
transcription and regulation, cell cycle, intracellular protein traffic.
A small number of down-regulated genes were also involved in
oncogenesis like runt-related transcription factor 3 (RUNX3),
SMAD family member 7 (SMAD7), PHD finger protein 17
(PHF17) as well as interleukin-1 receptor-associated kinase 2
(IRAK2), interleukin 2 receptor, beta (IL2RB), CD96 and SH2B
adaptor protein 3 (SH2B3) related to immune functions.
Therefore, in PANTHER database classification we found four
significant functional biological processes in our 238 down-
regulated genes list. However, no significant biological process
was found (after Bonferroni correction) when we evaluate all the
down-regulated genes associated to biological processes, according
with their fold changes drawn randomly from the overall
distribution of fold changes (data not shown).
Real time PCR validation
In all samples, we confirmed the expression of five up-regulated
genes (LY96, S100A12, ORM2, ORM1, RPL31) and four down
regulated genes (IL2RB, DNMT1, RUNX3 and IRF1)i nR A
patients, by real-time PCR. From microarray and real time PCR
Figure 3. Gene ontology analysis of the most representative biological processes represented by the 101 up-regulated genes in RA
patients. Gene Ontology (GO) analysis in the PANTHER database was applied for an interpretation of the biological processes that are represented
by the genes showing a higher significantly different expression level in RA patients compared to the controls. A and B - Biological processes with a
P value ,0.05 (red bars) were considered significant after Bonferroni correction. The GO analysis P-value was plotted on the y axis versus biological
processes on the x axis. A-The binomial statistics tool was used to compare our gene list to a reference list (NCBI: Homo sapiens genes) determining
the statistically significant (P value) over- or under- representation of PANTHER biological process. B-The Mann-Whitney U Test was used to
determine significant P values which indicate that the distribution (fold change) for each biological process is non-random and different from the
overall distribution. OP - Oxidative Phosphorylation; ET - Electron Transport; ID - Immunity and Defense; NNNAM - Nucleoside, Nucleotide and Nucleic
Acid Metabolism; T – Transport.
doi:10.1371/journal.pone.0006803.g003
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expression. The qPCR expression data of the nine genes showed a
high correlation with the microarray expression data (r=0.937)
(Figure 4).
Discussion
Microarray technology has been used to discriminate differenc-
es in gene expression profiles in tissues and PBMCs. Both synovial
tissue and PBMCs have been used to evaluate differences in the
gene expression profiles in RA [7,8]. If expression-based profiling
is to be of practical importance, sample accessibility becomes
crucial. In this context, peripheral mononuclear cells are key
sentinels of host defence, being used to identify novel disease
mediators, disease variants and treatment responses [7,29,30].
Transcriptome studies using Illumina and other technologies
showed that each approach was able to detect specific genes,
meaning an increase in knowledge by each platform [16–18]. To
complete previous studies on RA with Affymetrix or double colour
microarrays, we decided to use Illumina technology. Our study did
not confirm a specific expression for the genes regulated by
interferon type I, as described in a RA large-scale expression
profiling [8] (two colours analysis protocol using Stanford
University microarrays) (data not shown). Our analysis revealed
only one significantly increased biological mechanism: Immunity
and Defense. This process was already highlighted by other studies
in RA, as several genes that we described (S100A8, S1000A9,
S100A12 and AIF1). Additionally, our study identified new genes
like LY96/MD-2, NFAT5, TXN, CAMP/LL37, ORM1, ORM2,
SLC11A1, PGLYRP1 and F5. These genes are involved in different
functional Immunity and Defense related mechanisms as pro-
inflammation, anti-microbial activity, oxidative and osmotic
cellular stress and immunomodulatory functions (Figure 5).
The S100 calcium-binding proteins (S100A8, S100A9, and
S100A12) are characterized by strong prevalence in cells of
myeloid origin. Activated phagocytes expressing S100A8 and
S100A9 proteins are among the first cells infiltrating inflammatory
lesions in the synovium [31]. The expression of S100A8 and
S100A9 was found to be strongest at the cartilage-pannus junction,
which is the prime site of cartilage destruction and bone erosion in
arthritis [32]. S100A12 is strongly expressed in inflamed synovial
tissue, whereas it is nearly undetectable in synovia of control
subjects or patients after successful treatment [33]. Further studies
showed increased levels of S100A8/S100A9 and S100A12
concentrations in synovial fluid (SF) and serum in RA patients
[34–36]. In addition, S100A9, S100A8 and S100A12 levels were
associated with body mass index, presence of ACPA and RF and
presence of ACPA, respectively [37]. Furthermore, several
expression profiling studies in PBMCs showed a highly expression
of S100A8, S100A9 and S100A12 in RA patients compared to
controls [8,38,39]. Therefore, pro-inflammatory S100 proteins are
attractive therapeutic targets for immune interventions in the
treatment of RA.
Human allograft inflammatory factor-1 (AIF-1) is a Ca2+-
binding EF-hand protein encoded within the major histocompat-
ibility complex class (MHC) III region of chromosome 6. AIF-1 is
produced by macrophages and lymphocytes, and its synthesis is
Table 2. Differentially up-regulated transcripts linked to Immunity and Defense biological process in RA patients.
Gene Bank Name
Genome
Location
GeneID
(NCBI)
Transcript
Identifier
Fold Change RA
vs Controls
S100A8 S100 calcium binding protein A8 1q21 6279 NM_002964.3 2.9
S100A9 S100 calcium binding protein A9 1q21 6280 NM_002965.2 2.0
S100A12 S100 calcium binding protein A12 1q21 6283 NM_005621.1 1.8
AIF1 Allograft inflammatory factor 1 6p21.3 199 NM_001623.3 1.6
TXN Thioredoxin 9q31 7295 NM_003329.1 2.1
NFAT5 Nuclear factor of activated T-cells 5, tonicity-responsive 16q22.1 10725 NM_173215.1 1.3
CAMP (LL37) Cathelicidin antimicrobial peptide 3p21.3 820 NM_004345.3 2.5
LY96 (MD-2) Lymphocyte antigen 96 8q21.11 23643 NM_015364.2 2.6
ORM1 Orosomucoid 1 9q31–q32 5004 NM_000607.1 2.7
ORM2 Orosomucoid 2 9q32 5005 NM_000608.2 1.5
SLC11A1 (NRAMP1) Solute carrier family 11, member 1 2q35 6556 NM_000578.3 1.5
PGLYRP1 Peptidoglycan recognition protein 1 19q13.2–q13.3 8993 NM_005091.1 2.0
F5 Coagulation factor V 1q23 2153 NM_000130.4 1.7
doi:10.1371/journal.pone.0006803.t002
Figure 4. Correlation between microarray and real time PCR
data. The scatter plot compares mean expression of RA patients/
controls ratio for nine genes. Each point represents the RA patients/
controls ratio from the microarray (y axis) and real time PCR (x axis).
Pearson correlation coefficient is indicated in the scatter plot.
doi:10.1371/journal.pone.0006803.g004
RA Gene Expression Profiling
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Kimura et al. have demonstrated that AIF-1 is expressed in
synovial and mononuclear cells in RA synovial tissue and increases
proliferation of cultured synoviocytes and IL-6 production by these
synoviocytes and PBMCs [41]. A recent study, showed an
increased expression of AIF1 mRNA in RA patients PMBCs
compared with controls as well as in synovial macrophages in the
lining layer of all the inflamed RA synovial membranes compared
with non-inflamed OA controls [42]. AIF-1 plays therefore an
important role in the pathogenesis of RA by affecting key processes
such as the activation of synovial cell proliferation and the
inflammatory cytokine cascade including IL-6 in joints and may
represent a new molecular target in RA therapy.
The LY96 (MD-2) acts as an extracellular adaptor protein in the
activation of TLR4 by the lipopolysaccharide (LPS) of Gram
negative bacteria, a well-known inducer of the innate immune
response [43]. Knockout studies in mice have demonstrated that
MD-2 is indispensable for LPS responses [44]. Multiple evidences
points to the potential importance of TLR signalling in RA
pathogenesis by means of the presence of different TLR ligands
and functional TLR receptors in inflamed joints from patients with
RA [45]. TLR4 mRNA is highly expressed in the synovium at
early stages of RA as well as at later stages of the disease. In vitro
stimulation of the RA synovial fibroblasts with TLR4 ligand (LPS)
produces a wide range of proinflammatory cytokines, chemokines,
and tissue destructive enzymes [46]. Recently, the potential value
of TLR4 or signals derived from this receptor as therapeutic
targets has become clearer - mainly as a result of studies in animal
models of joint inflammation but also in human RA [47].
Interestingly, in our study, mRNA TLR4 was up-regulated in RA
patients compared to controls but not significantly. Thus, the
TLR4-MD2-LPS complex could be involved in the activation of
synovial fibroblasts and contribute to the development of synovial
inflammation and joint destruction.
NFAT5, the primordial member of the NFAT family, is
expressed by almost all cells and is activated in response to osmotic
stress. In lymphocytes, NFAT5 controls the osmotic stress-induced
expression of several cytokines, including tumour-necrosis factor
(TNF) and lymphotoxin-b. NFAT5-deficient mice have impaired
T-cell function under hyperosmotic conditions and decreased
cellularity of the thymus and spleen [48]. In RA, NFAT5 mRNA is
expressed in proliferating RA-synovial fibroblasts (RA-SF) but not
in nonproliferating RA-SF. Furthermore, NFAT5 mRNA is
expressed in RA synovium - but not in normal individuals - as
well as at sites of bone destruction. NFAT5 could be then related
not only with proliferation but also with the activation and
invasion of RA-SF in vivo [49].
Oxidative stress to essential cell components caused by oxygen
free radicals is generally considered as a serious mechanism in RA
pathogenicity [50]. Thioredoxin (TXN), a cellular reducing
catalyst induced by oxidative stress, is involved in the stimulation
of the DNA-binding activity of NF-kb transcription factor [51].
Increased cytokine production driven by NF-kb can enhance
expression of vascular adhesion molecules that attract leucocytes
into the joint, as well as matrix metalloproteinases that help to
degrade the extracellular matrix [50]. TXN concentrations were
found significantly elevated in SF and serum of RA patients. The
positive correlation between the SF TXN and the serum C
Reactive Protein in the absence of a high concentration of SF
TNF-a may indicate that TXN is involved in the prolongation and
persistence of the RA inflammation, because high concentrations
of TXN could stimulate NF-kB activation in the presence of the
otherwise insufficient concentration of TNF-a [52]. Thus, TXN
monitoring in RA patients could provide useful information
regarding the extent of oxidative stress. Furthermore, truncated
thioredoxin (Txn80) stimulates monocytes/macrophages to induce
IL-12, implying that it is involved in immune inflammatory
reactions directing Th1 immunity and IFN-c production [53].
Figure 5. Biological functions of Immunity and Defense genes highlighted in our Rheumatoid Arthritis study. The genes differentially
expressed in Immunity and Defense process are stratified in four functional related mechanisms: pro-inflammation, anti-microbial activity, oxidative
and osmotic cellular stress and immunomodulatory functions.
doi:10.1371/journal.pone.0006803.g005
RA Gene Expression Profiling
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novel target gene induced by IFN-c [54]. RA is a Th1-driven
disease which has IFN-c as characteristic Th1 cytokine and
subsequently the TXN mRNA up-regulation in PBMCs could
suggest an involvement in RA IFN-c pathway.
CAMP (LL37) is an antimicrobial peptide which has a broad of
antimicrobial activity. LL-37 has the potential to participate in the
innate immune response both by killing bacteria and by recruiting
a cellular immune response [55]. Gilliet and Lande recently found
that LL37, overexpressed in psoriatic skin, is the key mediator of
plasmacytoid dendritic cells (pDCs) activation in psoriasis. LL37
converts nonstimulatory self-DNA into a potent trigger of pDCs to
produce IFN. pDCs respond to self-DNA if coupled with an
antimicrobial peptide, suggesting that modified self-DNA drives
autoimmunity in psoriasis by activating TLR9 [56]. In RA, recent
studies have described pDCs as perpetuators of synovial
inflammation and modulators of B cell responses in the synovial
tissue [57]. The mRNA up-regulation of the LL37 gene found in
RA patients comparing to controls in our study could be due to an
immunological response to infectious agents such as bacteria and
viruses. Moreover the LL37 over-expression could be implicated
in a pDCs-dependent mechanism involved in the perpetuation of
RA inflammation through the abolition of self-tolerance and
subsequent emergence of self-reactive lymphocytes.
Human alpha-1-acid glycoprotein (AGP) - also called oroso-
mucoid - is a 37-kDa molecule consisting of a heavily glycosylated
single polypeptide chain. Alpha-1-acid glycoprotein 1 (AGP1) and
alpha-1-acid glycoprotein 2 (AGP2), coded by ORM1 and ORM2
genes respectively, are positive acute phase proteins [58,59]. AGPs
plasma concentration may increase several fold during acute phase
reactions such as inflammation or chronic disease. AGPs have a
strong immunomodulatory function [60]. It was shown that under
pathological conditions not only the total concentration of AGPs
but its glycosylation pattern may be altered [59]. Smith and
colleagues have demonstrated that the AGPs populations in the
serum and synovial fluid of RA patients are distinct in terms of
glycosylation pattern. This discovery has direct functional
significance since only the serum AGPs population is capable of
blocking leucocyte adhesion [61]. Furthermore, Haston et al. have
shown that AGPs can influence MMP-13 activity. It is
hypothesized that AGPs may form part of a negative feedback
mechanism which is inadequate to prevent disease progression in
rheumatoid arthritis. These processes may exacerbate the
increased turnover of collagen characteristic of the disease [62].
These results suggest an interesting role for AGP in RA
pathogenesis.
SLC11A1 (formerly called NRAMP1) is a gene that is important
in macrophage-mediated natural resistance to a variety of
intracellular pathogens. Exogenous and endogenous agents that
mediate inflammation by activating the macrophage can cause
NRAMP1 translocation to the membrane of the phagolysosome,
where it serves as a cation transporter. The significant increase in
iron deposition observed in the synovial membrane of rheumatoid
arthritis patients, and foam cells in atherosclerotic lesions, could be
attributable to NRAMP1 [63]. In human RA synovium NRAMP1
was detected in macrophages and neutrophils in the linning and
subinitimal zone, as well as in inflammatory infiltrates, but was
absent in fibroblasts [64]. NRAMP1 has also pleiotropic effects on
macrophage function, including upregulation of chemokine/
cytokine gene, TNFa, IL-1b, inducible nitric oxide synthase
(iNOS), MHC expression as well as tumoricidal and antimicrobial
activity. These effects are involved in resistance to infection and
may also be involved in induction and maintenance of
autoimmune disease [65]. TNFa and IL-1b play important roles
in inflammation and tissue destruction of RA [66,67]. Bacterial or
viral infection may play a role in triggering the development of RA
and TNFa and iNOS are key players in enhanced antimicrobial
activity of activated macrophages [65].
PGRPs are innate immunity proteins, recognizing bacterial
peptidoglycan, and acting in antibacterial immunity. PGRP-1
seems to belong to the innate immune arm of effectors molecules,
such as antimicrobial peptides and C-type lectins, among others.
This protein was shown to be almost exclusively present as a
soluble protein in the granules of polymorphonuclear leucocytes
(PMN) [68]. Saha et al. examined the immunomodulating
activities of the PGRPs in a peptidoglycan-induced arthritis mice
model. They showed that a systemic injection of peptidoglycan
(PG) or muramyldipeptide (MDP) induces an acute arthritis of the
joints of the feet in BalbC mice. Peptidoglycan-induced arthritis
PGLYRP-1
2/
2 mice, had a MDP-induced activation of proin-
flammatory genes than WT mice. Moreover, PGLYRP-1
2/
2
mice have longer-lasting MDP-induced arthritis than WT mice.
The anti-inflammatory function of PGLYRP-1 manifests itself
only in the later stages of MDP-induced arthritis, which is
consistent with the local release of PGLYRP-1 from PMN granules
after PMNs’ arrival into the mice foot [69]. These data point to
that PGRP-1 could have a specialized but nevertheless significant
role in signalling events like arthritis in mammals.
The multi-step coagulation complex system is activated by tissue
factor (TF), which is exposed to blood. In this process, factor 5
(FV) is cleaved and activates factor Va (FVa). After several proteins
interactions, the prothrombinase complex (FXa–FVa) converts
prothrombin to thrombin which is generated in a large amount.
Thrombin activates FV and FVIII and platelets converting
fibrinogen to a fibrin clot [70]. Accumulation of fibrin in the
RA synovium exceeds that in control tissue by a wide margin and
represents one of the most striking pathologic features of
rheumatoid synovitis. For some time, this fibrin deposition has
been considered to be a serious contributor to permanent damage
by maintaining a vicious circle of inflammation [71,72]. In the
extravascular coagulation at the arthritic synovial joint sequential
activity of factor Xa (in the presence of cofactor Va) and of
thrombin leads to fibrin deposition in the joint [73]. Thus, mRNA
F5 up-regulation in RA patients could enhance the production of
factor V that under cleavage produces factor Va. This Va increase
could lead to the augmentation of thrombin and consequently
fibrin in RA joints.
In conclusion, our study highlighted several new genes (LY96/
MD-2, NFAT5, TXN, CAMP/LL37, ORM1, ORM2, SLC11A1,
PGLYRP1 and F5) in PBMCs of RA patients that could contribute
in the identification of innovative clinical biomarkers for diagnostic
procedures and therapeutic interventions. Nevertheless, compar-
ative analysis with another disease involving an inflammatory
process could clarify the relation between the expression profiling
and the pathophysiological processes specifically involved in
Rheumatoid Arthritis.z
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